DARVON-N
LOE Approachingpropoxyphene napsylate
NDAORALTABLET
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DARVON-N (propoxyphene napsylate) is clinical pharmacology pharmacology propoxyphene is a centrally acting opiate analgesic. First approved in 1971.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON-N (propoxyphene napsylate) is an oral centrally-acting opioid analgesic approved in 1971 for pain management. It works through opioid receptor agonism and also exhibits local anesthetic properties via sodium channel inhibition, with its metabolite norpropoxyphene showing enhanced potency. The drug is indicated for mild to moderate pain relief in patients requiring oral analgesia.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, indicating shrinking commercial teams and shift toward generic defense or divestment strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacology Propoxyphene is a centrally acting opiate analgesic. In vitro studies demonstrated propoxyphene and the metabolite norpropoxyphene inhibit sodium channels (local anesthetic effect) with norpropoxyphene being approximately 2-fold more potent than propoxyphene and…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.